Phaseline

Targets › SPPL3

SPPL3 (Signal peptide peptidase-like 3): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.

Intramembrane-cleaving aspartic protease (I-CLiP) that cleaves type II membrane protein substrates in or close to their luminal transmembrane domain boundaries. Acts like a sheddase by mediating the proteolytic release and secretion of active site-containing ectodomains of glycan-modifying glycosidase and glycosyltransferase enzymes such as MGAT5, B4GAT1 and B4GALT1. (UniProt, Q8TCT6)

Open in Phaseline: the race on SPPL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chinese PLA General HospitalTCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T c
Allogeneic CAR-T cell therapy targeting CD19 with TCR alpha/beta chain (TRAC) and SPPL3 ge
TRBC, SPPL3, CD19, TCRAPhase 1Acute Lymphocytic Leukemia; Non-hodgkin LymphomaFeb 2027

Conditions

Acute Lymphocytic Leukemia (1) Non-hodgkin Lymphoma (1)

Modalities

mixed (1)

Companies

Chinese PLA General Hospital (1)

Related targets

TRBC (1) CD19 (1) TCRA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.